OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Haigentz on the Impact of Immunotherapy in Head and Neck Cancer

September 20th 2018

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center, medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the impact that immunotherapy has had on the treatment of patients with head and neck cancer.

Dr. Sapisochin on Neoadjuvant Treatment for HCC

September 20th 2018

Gonzalo Sapisochin, MD, assistant professor of surgery, University of Toronto, discusses neoadjuvant treatment for patients with hepatocellular carcinoma.

Dr. Kalinsky on CNS Involvement in HER2+ Breast Cancer

September 20th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.

Dr. Shah on Treatment of Patients with p53-Mutated MCL

September 20th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Dr. Bunn on the Treatment of Early-Stage Lung Cancer

September 20th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the treatment of patients with early-stage non–small cell lung cancer.

Dr. Konecny on the Value of PARP Inhibitors in Ovarian Cancer

September 19th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Sonpavde on Remaining Questions With Immunotherapy in Bladder Cancer

September 19th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer.

Dr. Ali on Adjuvant Studies With Biosimilars in Oncology

September 19th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses adjuvant studies with biosimilars in oncology.

Dr. Eng Discusses the ADORE Trial in Rectal Cancer

September 19th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Dr. Dent Discusses Ipatasertib in Triple-Negative Breast Cancer

September 19th 2018

Rebecca Dent, MD, senior consultant, National Cancer Center, Singapore, discusses ipatasertib in the treatment of patients with triple-negative breast cancer.

Dr. Cohen Discusses the Treatment of MCL

September 19th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the treatment of patients with mantle cell lymphoma.

Dr. Finn on Considerations for Lenvatinib in Liver Cancer

September 19th 2018

Richard Finn, MD, associate professor of medicine, University of California, Los Angeles David Geffen School of Medicine, discusses the role of lenvatinib in the treatment of patients with liver cancer.

Dr. Van Veldhuizen Discusses Combination Therapy in RCC

September 19th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.

Dr. Tasian on Challenges in Treating Pediatric Patients With Ph-Like ALL

September 19th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the challenges in treating pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).

Dr. Riedel on the Role of Immunotherapy in Uterine Sarcoma

September 19th 2018

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the emerging role of immunotherapy in uterine sarcoma.

Dr. Daskivich on the Future Landscape of Prostate Cancer

September 19th 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Dr. Naumann on Improving Outcomes With Chemotherapy in Ovarian Cancer

September 19th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses improving outcomes with chemotherapy for the neoadjuvant treatment of patients with ovarian cancer.

Dr. Rule on the Role of BTK Inhibitors in MCL

September 18th 2018

Simon Rule, MD, PhD, professor of Hematology at Plymouth University Medical School, United Kingdom, discusses the role of BTK inhibitors in the treatment of patients with mantle cell lymphoma.

Dr. Brahmer on Immunotherapy in Stage IV NSCLC

September 18th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses immunotherapy for patients with stage IV non–small cell lung cancer.

Dr. Tolaney Reflects on Data from the PERSEPHONE Trial

September 18th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, reflects on data from the PERSEPHONE trial in HER2-positive breast cancer.